Overview

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Status:
Completed

Trial end date:
2015-11-01

Target enrollment:

Participant gender:

Summary

It is well known that substantial interindividual variability of CYP3A4/1A2-phenotype activity is an important contributor to individual differences in the sensitivity to the frequently used tyrosine kinase inhibitors sunitinib and erlotinib. This study tests the potential for CYP-phenotyping to predict individual pharmacology and derive dosing algorithms for more tailored treatment of these drugs.

Phase:

Phase 4

Details

Lead Sponsor:

Markus Joerger

Collaborator:

University of Basel

Treatments:

Caffeine
Erlotinib Hydrochloride
Midazolam
Sunitinib